AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVS
  4. [SCHEDULE 13G] Novartis AG SEC Filing

[SCHEDULE 13G] Novartis AG SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source:

Stock NVS logo
Novartis

NYSE:NVS

NVS Rankings

#54 Ranked by Market Cap
N/A Ranked by Dividends

NVS Latest News

Aug 11, 2025
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sj枚gren's disease
Jul 31, 2025
Novartis twice-yearly* Leqvio庐 (inclisiran) receives FDA approval for new indication enabling first-line use
Jul 3, 2025
Novartis provides update on Phase III GCAptAIN study of Cosentyx庐 in giant cell arteritis (GCA)
Apr 2, 2025
Novartis receives FDA accelerated approval for Vanrafia庐 (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Mar 20, 2025
Novartis receives third FDA approval for oral Fabhalta庐 (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

NVS Latest SEC Filings

Jul 17, 2025
[6-K] Novartis AG Current Report (Foreign Issuer)
Jul 17, 2025
[6-K] Novartis AG Current Report (Foreign Issuer)

NVS Stock Data

219.72B
1.94B
0%
7.26%
0.22%
Drug Manufacturers - General
Healthcare
Switzerland
Basel